Immunotherapeutic Strategies for High-Risk Bladder Cancer

Padmanee Sharma; Lloyd J. Old; James P. Allison

doi:10.1053/j.seminoncol.2006.12.004

Immunotherapeutic Strategies for High-Risk Bladder Cancer

Padmanee Sharma, Lloyd J. Old, James P. Allison

Genitourinary Medical Oncology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.

Original language	English (US)
Pages (from-to)	165-172
Number of pages	8
Journal	Seminars in oncology
Volume	34
Issue number	2
DOIs	https://doi.org/10.1053/j.seminoncol.2006.12.004
State	Published - Apr 2007

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1053/j.seminoncol.2006.12.004

Cite this

@article{a65bcde0ab48475f89955dccf3099946,

title = "Immunotherapeutic Strategies for High-Risk Bladder Cancer",

abstract = "Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Gu{\'e}rin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.",

author = "Padmanee Sharma and Old, {Lloyd J.} and Allison, {James P.}",

note = "Funding Information: Supported in part by the UTMDACC Bladder Cancer SPORE Career Development Award 5P50 CA091846 04 (PP-CDP4), Physician Scientist Program Award and Institutional Research Grant (P. Sharma). ",

year = "2007",

month = apr,

doi = "10.1053/j.seminoncol.2006.12.004",

language = "English (US)",

volume = "34",

pages = "165--172",

journal = "Seminars in oncology",

issn = "0093-7754",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Immunotherapeutic Strategies for High-Risk Bladder Cancer

AU - Sharma, Padmanee

AU - Old, Lloyd J.

AU - Allison, James P.

N1 - Funding Information: Supported in part by the UTMDACC Bladder Cancer SPORE Career Development Award 5P50 CA091846 04 (PP-CDP4), Physician Scientist Program Award and Institutional Research Grant (P. Sharma).

PY - 2007/4

Y1 - 2007/4

N2 - Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.

AB - Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=33947214949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947214949&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2006.12.004

DO - 10.1053/j.seminoncol.2006.12.004

M3 - Article

C2 - 17382800

AN - SCOPUS:33947214949

SN - 0093-7754

VL - 34

SP - 165

EP - 172

JO - Seminars in oncology

JF - Seminars in oncology

IS - 2

ER -

Immunotherapeutic Strategies for High-Risk Bladder Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this